King's College London

Research portal

Crescendo response to rituximab in oral pemphigus vulgaris: a case with 7-year follow-up

Research output: Contribution to journalArticle

D T Greenblatt, E C Benton, R W Groves, J F Setterfield

Original languageEnglish
Pages (from-to)529-32
Number of pages4
JournalClinical and Experimental Dermatology
Volume41
Issue number5
DOIs
PublishedJul 2016

King's Authors

Abstract

Pemphigus vulgaris (PV) is an autoimmune blistering disease affecting the skin and mucous membranes. Rituximab, a CD20 chimeric monoclonal antibody, has efficacy in PV management. We report a case of severe oral PV that showed a progressive response to repeated courses of rituximab, culminating in a rapid response within 4 weeks following severe relapse 4 years after initial therapy. It demonstrates the progressively shorter time to achieve partial or complete remission following rituximab infusions, combined with minimal adjuvant therapy over a 7-year follow-up period.

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454